Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class (Descending) Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00078-0438-15 00078-0438 Imatinib Mesylate Gleevec 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral May 15, 2001 May 31, 2017 In Use
00078-0640-70 00078-0640 Ceritinib Zykadia 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK Oral April 29, 2014 Feb. 29, 2020 In Use
00310-7820-30 00310-7820 Vandetanib Caprelsa 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Oral July 25, 2011 May 31, 2020 No Longer Used
00310-7840-30 00310-7840 Vandetanib Caprelsa 300.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, EGFR Oral July 25, 2011 May 31, 2020 No Longer Used
00078-1091-20 00078-1091 asciminib SCEMBLIX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct. 29, 2021 In Use
00078-1091-94 00078-1091 asciminib SCEMBLIX 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct. 29, 2021 In Use
00078-1098-20 00078-1098 asciminib SCEMBLIX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct. 29, 2021 In Use
00078-1098-30 00078-1098 asciminib SCEMBLIX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct. 29, 2021 In Use
00078-1098-94 00078-1098 asciminib SCEMBLIX 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ABL/BCR-ABL1 Oral Oct. 29, 2021 In Use
63020-0040-12 63020-0040 Mobocertinib EXKIVITY 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Sept. 15, 2021 In Use

Found 10,000 results in 4 millisecondsExport these results